- The global Uveitis Drug Market is anticipated to gain significant momentum during the forecast period, with a CAGR of 8.2% from 2025 to 2032.
- Uveitis—comprising anterior, intermediate, posterior, and panuveitis types—is a major cause of preventable vision loss, often associated with systemic autoimmune diseases such as sarcoidosis, ankylosing spondylitis, and Behçet’s disease.
- The market is being supported by increasing demand for novel corticosteroid-sparing therapies, expanding pipelines of immunomodulatory drugs, and development of sustained-release formulations.
- Increasing healthcare expenditure, improved access to ophthalmologic care, and expanding reimbursement policies in emerging economies are expected to further accelerate market growth
